David W Cadotte1, Michael G Fehlings. 1. Division of Neurosurgery, University of Toronto, and Neural Repair and Regeneration, Spinal Program, University Health Network, Toronto Western Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND: Spinal cord injury (SCI) is a devastating event often resulting in permanent neurologic deficit. Research has revealed an understanding of mechanisms that occur after the primary injury and contribute to functional loss. By targeting these secondary mechanisms of injury, clinicians may be able to offer improved recovery after SCI. QUESTIONS/PURPOSES: In this review, we highlight advances in the field of SCI by framing three questions: (1) What is the preclinical evidence for the neuroprotective agent riluzole that has allowed this agent to move into clinical trials? (2) What is the preclinical evidence for Rho antagonists that have allowed this group of compounds to move into clinical trials? (3) What is the evidence for early surgical decompression after SCI? METHODS: We conducted a systematic review of MEDLINE and EMBASE-cited articles related to SCI to address these questions. RESULTS: As a result of an improved understanding of the secondary mechanisms of SCI, specific clinical strategies have been established. We highlight three strategies that have made their way from bench to bedside: the sodium-glutamate antagonist riluzole, the Rho inhibitor Cethrin, and early surgical decompression. Each of these modalities is under clinical investigation. We highlight the fundamental science that led to this development. CONCLUSIONS: As our understanding of the fundamental mechanisms of SCI improves, we must keep abreast of these discoveries to translate them into therapies that will hopefully benefit patients. We summarize this process of bench to bedside with regard to SCI.
BACKGROUND:Spinal cord injury (SCI) is a devastating event often resulting in permanent neurologic deficit. Research has revealed an understanding of mechanisms that occur after the primary injury and contribute to functional loss. By targeting these secondary mechanisms of injury, clinicians may be able to offer improved recovery after SCI. QUESTIONS/PURPOSES: In this review, we highlight advances in the field of SCI by framing three questions: (1) What is the preclinical evidence for the neuroprotective agent riluzole that has allowed this agent to move into clinical trials? (2) What is the preclinical evidence for Rho antagonists that have allowed this group of compounds to move into clinical trials? (3) What is the evidence for early surgical decompression after SCI? METHODS: We conducted a systematic review of MEDLINE and EMBASE-cited articles related to SCI to address these questions. RESULTS: As a result of an improved understanding of the secondary mechanisms of SCI, specific clinical strategies have been established. We highlight three strategies that have made their way from bench to bedside: the sodium-glutamate antagonist riluzole, the Rho inhibitor Cethrin, and early surgical decompression. Each of these modalities is under clinical investigation. We highlight the fundamental science that led to this development. CONCLUSIONS: As our understanding of the fundamental mechanisms of SCI improves, we must keep abreast of these discoveries to translate them into therapies that will hopefully benefit patients. We summarize this process of bench to bedside with regard to SCI.
Authors: Gregory D Carlson; Carey D Gorden; Heather S Oliff; Jay J Pillai; Joseph C LaManna Journal: J Bone Joint Surg Am Date: 2003-01 Impact factor: 5.284
Authors: James Guest; Mohammed A Eleraky; Paul J Apostolides; Curtis A Dickman; Volker K H Sonntag Journal: J Neurosurg Date: 2002-07 Impact factor: 5.115
Authors: Arnaud Dubory; Elisabeth Laemmel; Anna Badner; Jacques Duranteau; Eric Vicaut; Charles Court; Marc Soubeyrand Journal: J Vis Exp Date: 2015-05-07 Impact factor: 1.355
Authors: Joshua Stephen Catapano; Gregory William John Hawryluk; William Whetstone; Rajiv Saigal; Adam Ferguson; Jason Talbott; Jacqueline Bresnahan; Sanjay Dhall; Jonathan Pan; Michael Beattie; Geoffrey Manley Journal: World Neurosurg Date: 2016-08-23 Impact factor: 2.104